sST2 is a member of the interleukin-1 (IL-1) receptor family and it can be found in a transmembrane form (ST2 ligand or ST2L) and a soluble, circulating form (sST2). IL-33 when bound with ST2L protects the myocardium against hypertrophy and cardiac fibrosis. However Soluble ST2 acts as a decoy receptor for IL-33 and prevents the IL-33/ST2L interaction.
Higher concentration of soluble ST2 is associated with increased myocardial fibrosis, adverse cardiac remodeling, and
worse cardiovascular outcomes. 1, 2
Studies shows that the changes in sST2 level during follow up patients admitted with acute HF represent a strong, independent predictor of the composite endpoint of all-cause mortality or readmission for HF over at least 1 year follow-up. 1, 3, 4
Biomarkers have become an integral part of medicine, aiding in the diagnosis and treatment of numerous conditions. Natriuretic peptides, troponin, ST2 and procalcitonin, all provide significant information for the doctor to know which is the best treatment for a patient presenting at the hospital with chest pain, shortness of breath, sign of infections, etcetera.
Biomarkers also can help decide on appropriateness of discharge and follow up frequency.
All these parameters work together to provide the most vivid picture for the clinician to consider and adapt the therapy to the single patient.5, 6
|Compatible Device||ichroma™ II|
|Detection Range||3.1~200 ng/mL|
|Sample Type||Whole Blood, Serum,
Plasma, Capillary Blood
|Reaction Time||12 minutes|